digital health companies glp-1 programs 7 Telehealth Platforms Changing How We Access GLP-1s Technologies enabling long-term health outcomes

Health Canada has approved six medications specifically for chronic weight management: orlistat (Xenical), liraglutide (Saxenda), naltrexone-bupropion (Contrave), semaglutide (Wegovy), tirzepatide (Zepbound), and setmelanotide (Imcivree, for rare genetic forms of obesity only)

Agents such as semaglutide and tirzepatide have demonstrated especially notable efficacy in this regard, further reinforcing the concept that targeted weight management can meaningfully influence cardiovascular outcomes

The World Anti-Doping Agency added BPC-157 to its Prohibited List in January 2022 under category S0 (Non-Approved Substances)

Omega-3 soft gels vary in their DHA and EPA content, but the label will show you how much is in there

However, recent research has raised questions about whether some GLP-1 medications, especially semaglutide, may be associated with a higher risk of a rare but serious eye condition called NAION